Torrent Pharma gets USFDA EIR for Indrad facility

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-08-30T11:38:08+05:30 | Updated On 30 Aug 2024 11:38 AM IST

Ahmedabad: Torrent Pharma has informed in a BSE filing that the U.S. Food and Drug Administration (USFDA) has issued Establishment Inspection Report (“EIR”) with Voluntary Action Indicated (“VAI”) classification for the manufacturing facility at Indrad, Gujarat. The inspection has now been successfully closed by the USFDA.

VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action

The USFDA had conducted inspection at the facility from 03-Jun-24 to 12-Jun-24 and issued five observations.

Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC).

torrent pharmatorrent pharma newsUSFDAUSFDA inspection

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751